
Program Officer
Drug Development and Clinical Sciences Branch
Therapeutic Research Program
Division of AIDS
National Institutes of Allergy and Infectious Diseases
Education
- Cornell University, Ithaca, N.Y. 1978-1982, B.S., Biology
- Temple University School of Pharmacy, Philadelphia, PA. 1982-1985, B.S, Pharmacy
- Uniformed Services University of the Health Sciences, Bethesda, Md. 1986-1992, Ph.D., Pharmacology
- Johns Hopkins Bloomberg School of Public Health and Hygiene 2008-10, Coursework in the Graduate Training Program in Clinical Investigation (GTPCI)
Residencies/Fellowships
- Residency in Clinical Pharmacy, Pharmacy Dept., National Institutes of Health, Warren G. Magnusen Clinical Center 1985-1986
- Staff Fellow, Section on Pharmacology, Laboratory of Biochemical Pharmacology, National Institute of Diabetes Digestive and Kidney Disease 1992-1995
Selected Publications
- Godfrey, C; Thigpen, M., Crawford, K.W., et al. Global HIV Drug Resistance: A Pespective and Report of a NIAID consultation.Journal of Infectious Diseases, 2017, (available online) https://academic.oup.com/jid/article/doi/10.1093/infdis/jix137/3869642/Global-HIV-Antiretroviral-Drug-ResistanceA?guestAccessKey=4c9d60f4-8ce8-4e12-bb58-970540eef976
- Jean-Phillipe, P., Gnanashamugam, D, Speigel, H., Crawford, K.W. et al. HIV Birth Testing and Linkage to Care for HIV Infected Infants: Workshop Synopsis. AIDS, 2017, in press
- Crawford, K.W., Wakabi, S., Kibuuka, H., Magala, F., Keshinro, B., Okoye, I., Akintunde, E., Hamm, T. East Meets West: A Description of HIV-1 Drug Resistance Mutation Patterns of Patients failing First Line Therapy in PEPFAR-clinics from Uganda and Nigeria. AIDS Research and Human Retroviruses, 2014, 30(8):796-9
- Crawford, K.W., Wakabi, S., Kibuuka, H.,Magala, F., Liu, M., Hamm, T. Evaluation of Treatment Outcomes for Patients on First-Line Regimens in US Presidents Emergency Plan for AIDS Relief (PEPFAR) Clinics in Uganda: Predictors of Virologic and Immunologic Response from RV288 Analyses. HIV Medicine, 2014, 15 (8):470-78
- Crawford K.W., Njeru D, Maswai J, Omondi M, Apollo D, Kimetto J, Gitonga L, Munyao J, Langat R, Aoko A, Tarus J, Khamadi S, Hamm TE Occurrence of etravirine/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy. AIDS, 2014, 28(3):442-5.
- Crawford,K.W., Li,X., Xu X.,Abraham,A., Dobs, A., Margolick,J., Pallella, F., Kingsley,L., Witt,M., Brown, T. Lipodystrophy and Inflammation Predict Grip Strength in HIV-infected Men: the MACS Body Composition Substudy. AIDS Research and Human Retroviruses, 2013, 29(8):1138-45.
- Crawford, KW, Ripin, DHB Levin, A, Flexner, C; Optimizing The Manufacturing, Formulation, and Dose of Antiretroviral Drugs for more Cost-efficient Delivery in Resource-constrained Settings: A Consensus Conference. Lancet Infectious Diseases, 2012, 12:550-60
- Crawford, K.W. and Flexner, C., Does Dosing frequency Matter with Antiretroviral Drugs?, Treatment Strategies–AIDS,2010,1:34-39 (http://viewer.zmags.com/publication/d4b7caf8#/d4b7caf8/1)
- Crawford KW, Li C, Keung A, Su Z, Hughes MD, Greaves W, Kuritzkes D, Gulick R, Flexner C; and for the ACTG A5211 Study TeamPharmacokinetic/pharmacodynamic Modeling of the Antiretroviral Activity of the CCR5 Antagonist Vicriviroc in the Treatment-Experienced HIV Patients. Journal of the Acquired Immune Deficiency Syndrome, 2010, 53 (5):598-605
- Crawford KW, Spritzler J, Kalayjian RC, Parsons T, Landay A, Pollard R, Stocker V, Lederman MM, Flexner C; AIDS Clinical Trials Protocol 5015 Team. Age-related Changes in the Plasma Concentrations of the HIV Protease Inhibitor Lopinavir. AIDS Research and Human Retroviruses, 2010, 26:635-643